Tara Nickerson, PhD, is Chief Executive Officer of Therini Bio, a clinical-stage biopharmaceutical company developing novel therapies for neuroinflammation. Tara is also currently an Independent Director of Mispro, a company offering contract vivarium for preclinical research. Tara was previously a founding team member and Chief Business Officer of Maze Therapeutics (Nasdaq: MAZE) and Prothena Corporation (Nasdaq: PRTA), and held Vice President roles in Business & Corporate Development at Neotope Biosciences and Elan Pharmaceuticals. Tara has a PhD in Experimental Medicine and a BSc in Biology from McGill University as well as an MBA from the University of California at Berkeley, Haas School of Business.